Collignon Peter, Beggs John J
Australian Capital Territory Pathology, Canberra Hospital, Garran, Australian Capital Territory, Australia.
Medical School, Australian National University, Canberra, Australia.
JAC Antimicrob Resist. 2020 Sep;2(3):dlaa051. doi: 10.1093/jacamr/dlaa051. Epub 2020 Jul 17.
Antimicrobial resistance (AMR) is affected by many factors, but too much of our focus has been on antimicrobial usage. The major factor that drives resistance rates globally is spread. The COVID-19 pandemic should lead to improved infection prevention and control practices, both in healthcare facilities and the community. COVID-19 will also have ongoing and profound effects on local, national and international travel. All these factors should lead to a decrease in the spread of resistant bacteria. So overall, COVID-19 should lead to a fall in resistance rates seen in many countries. For this debate we show why, overall, COVID-19 will not result in increased AMR prevalence. But globally, changes in AMR rates will not be uniform. In wealthier and developed countries, resistance rates will likely decrease, but in many other countries there are already too many factors associated with poor controls on the spread of bacteria and viruses (e.g. poor water and sanitation, poor public health, corrupt government, inadequate housing, etc.). In these countries, if economies and governance deteriorate further, we might see even more transmission of resistant bacteria.
抗菌药物耐药性(AMR)受多种因素影响,但我们过多地将重点放在了抗菌药物的使用上。全球推动耐药率上升的主要因素是传播。新冠疫情应促使医疗机构和社区改进感染预防与控制措施。新冠疫情还将对本地、国家和国际旅行产生持续且深远的影响。所有这些因素都应能减少耐药菌的传播。所以总体而言,新冠疫情应会使许多国家的耐药率下降。在本次辩论中,我们将阐述为何总体上新冠疫情不会导致抗菌药物耐药性患病率上升。但在全球范围内,抗菌药物耐药率的变化并不一致。在较富裕和发达的国家,耐药率可能会下降,但在许多其他国家,已经存在太多与细菌和病毒传播控制不力相关的因素(例如水和卫生条件差、公共卫生状况不佳、政府腐败、住房不足等)。在这些国家,如果经济和治理进一步恶化,我们可能会看到耐药菌的传播更加严重。